Current Treatment Options in Gastroenterology

, Volume 3, Issue 5, pp 403–424 | Cite as

Pediatric inflammatory bowel disease

  • Eric Vasiliauskas

Opinion statement

The combination of an unprecedented number of new therapeutic options (Fig. 1), along with new insights in how to optimize currently available therapies and advances in our understanding of disease pathogenesis, present many exciting new aspects to the management of patients with inflammatory bowel disease (IBD). Clinical management paradigms must evolve in parallel to keep pace with these advances. Traditional pediatric IBD regimens have underutilized combination therapies (Fig. 2) and immunomodulatory agents. Increased appreciation for steroid side effects is leading to a shift away from their inclusion in maintenance regimens. Immunomodulators are being introduced earlier in the course of disease for maintenance of remission and growth promotion. Recognition that the sole signs of active disease in children and adolescents may be growth and maturational delay, despite a relative lack of gastrointestinal symptoms, should prompt earlier, more aggressive interventions. When more potent, rapidly acting interventions such as infliximab, cyclosporine (CSA), or tacrolimus are considered, they should generally be co-administered with agents such as 6-mercaptopurine (6-MP) or azathioprine (AZA) for longer-term disease suppression.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Burbige EJ, Huang SS, Bayless TM: Clinical manifestations of Crohn’s disease in children and adolescents. Pediatrics 1975, 55:866–871.PubMedGoogle Scholar
  2. 2.
    Gryboski J, Hillemeier C: Inflammatory bowel disease in children. Med Clin North Am 1980, 64:1185–1202.PubMedGoogle Scholar
  3. 3.
    Plevy SE, Taylor K, DeWoody KL, et al.: Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn’s disease patients with poor clinical responses to anti-TNF monoclonal antibody (cA2). Gastroenterology 1997, 112:A1062. This subanalysis of the infliximab trial reported by Targan et al. [66] suggests that stratification of CD patients based on serum immune and genetic markers may ultimately allow patients to be treated more selectively with specific cytokinedirected therapies.Google Scholar
  4. 4.
    Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, in press. The potential benefits of combining the patient’s TPMT genotype with thiopurine metabolite levels as a means of individualizing and optimizing 6-MP/AZA therapy are described in this study.Google Scholar
  5. 5.
    Vasiliauskas EA: Monoclonal antibody therapy in inflammatory bowel disease. In Inflammatory Bowel Diseases: Nestlé Nutrition Workshop Series Clinical & Performance Programme. Edited by Bistrian BR, Walker-Smith JA. Nestec Ltd., Vevey/S. Karger AG, Basel; 1999, 2:237–255. This article reviews the rationale and role of cytokine specific monoclonal antibody therapies directed against TNF-a in the treatment of IBD and discusses specific considerations relevant to the application of this form of therapy in patient care.Google Scholar
  6. 6.
    Kam L, Vasiliauskas EA, Landers CJ, et al.: Magnitude of response to Remicade correlates with marker antibody expression. Gastroenterology 1999, 116:A744(#G3232). This study suggests that responses to cytokine-specific interventions can be predicted based on pattern and magnitude of serum immune marker expression.Google Scholar
  7. 7.
    Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99:956–963.PubMedGoogle Scholar
  8. 8.
    Hanauer SB: Inflammatory bowel disease. N Engl J Med 1996, 334:841–848. This is an excellent general overview of therapies used to treat IBD.PubMedCrossRefGoogle Scholar
  9. 9.
    Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118:540–549.PubMedGoogle Scholar
  10. 10.
    Messori A, Brignola C, Trallori G, et al.: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994, 89:692–698.PubMedGoogle Scholar
  11. 11.
    Cohen MB, Seidman E, Winter H, et al.: Controversies in pediatric inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:203–227. This conference summary highlights issues related to the care pediatric patients with IBD.CrossRefGoogle Scholar
  12. 12.
    Winter HS, Ng S: Consensus conference on the evaluation of drugs to treat children with inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:101–131. These are the proceedings of a consensus conference held to evaluate issues regarding new and available therapies in IBD, and in particular, addresses issues specific to treating children and adolescents.CrossRefGoogle Scholar
  13. 13.
    Moody GA, Jayanthi V, Probert CS, et al.: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996, 8:1179–1183.PubMedGoogle Scholar
  14. 14.
    Pinczowski D, Ekbom A, Baron J, et al.: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994, 107:117–120.PubMedGoogle Scholar
  15. 15.
    Ferry GD, Kirschner BS, Grand RJ, et al.: Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993, 17:32–38.PubMedCrossRefGoogle Scholar
  16. 16.
    Munkholm P, Langholz E, Davidsen M, et al.: Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994, 35:360–362.PubMedGoogle Scholar
  17. 17.
    Sachar DB: Maintenance therapy in ulcerative colitis and Crohn’s disease. J Clin Gastroenterol 1995, 20:117–122.PubMedCrossRefGoogle Scholar
  18. 18.
    Whittington PF, Barnes HV, Bayless TM: Medical management of Crohn’s disease in adolescence. Gastroenterology 1977, 72:1338–1344. This study describes how continued suppression of disease activity promotes growth.PubMedGoogle Scholar
  19. 19.
    Kirschner BS: Ulcerative colitis and Crohn’s disease in children: diagnosis and management. Gastroenterol Clin North Am 1995, 24:99–117.PubMedGoogle Scholar
  20. 20.
    Fernando del Rosario J, Orenstein SR, et al.: Retrospective analysis of alternate-day prednisone maintenance therapy for Crohn’s disease. Clin Pediatr 1998, 37:413–419.Google Scholar
  21. 21.
    Marx G, Seidman EG: Inflammatory bowel disease in pediatric patients. Curr Opin Gastroenterol 1999, 15:322–325.PubMedCrossRefGoogle Scholar
  22. 22.
    Thomson ABR, Sadowski D, Jenkins R, et al.: Budesonide in the management of Crohn’s disease. Can J Gastroenterol 1997, 11:255–260.PubMedGoogle Scholar
  23. 23.
    Present DH, Korelitz BI, Wisch N, et al.: Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980, 302:981–987.PubMedCrossRefGoogle Scholar
  24. 24.
    George J, Present DH, Pou R, et al.: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996, 91:1711–1714.PubMedGoogle Scholar
  25. 25.
    Bouhnik Y, Lemann M, Mary JY, et al.: Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347:215–219.PubMedCrossRefGoogle Scholar
  26. 26.
    Pearson DC, May GR, Fick GH, et al.: Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 1995, 123:132–142.PubMedGoogle Scholar
  27. 27.
    Hawthorne AB, Logan RFA, Hawkey CJ, et al.: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992, 305:20–22.PubMedGoogle Scholar
  28. 28.
    Sandborn WJ: Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 1998, 33(S225):92–99. This is comprehensive review of 6-MP and AZA and issues related to their use in IBD.CrossRefGoogle Scholar
  29. 29.
    Markowitz J, Rosa J, Grancher K, et al.: Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 1990, 99:1347–1351.PubMedGoogle Scholar
  30. 30.
    Verhave M, Winter HS, Grand RJ: Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990, 117:809–814.PubMedCrossRefGoogle Scholar
  31. 31.
    Perrault J, Greseth JLM, Tremaine WJ: 6-mercaptopurine therapy in selected cases of corticosteroiddependent Crohn’s disease. Mayo Clin Proc 1991, 66:480–484.PubMedGoogle Scholar
  32. 32.
    Markowitz J, Grancher K, Mandel F, et al.: Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Am J Gastroenterol 1993, 88:44–48. This report summarizes the results of a survey of pediatric gastroenterologists’ attitudes toward the use of immunosuppressive agents in the treatment of children with IBD and highlights the cumulative pediatric experience with 6-MP and AZA.PubMedGoogle Scholar
  33. 33.
    Kader HA, Mascarenhas MR, Piccoli DA, et al.: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999, 28:54–58.PubMedCrossRefGoogle Scholar
  34. 34.
    Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813–821.PubMedCrossRefGoogle Scholar
  35. 35.
    Connell WR, Kamm MA, Dickson M, et al.: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249–1252.PubMedCrossRefGoogle Scholar
  36. 36.
    Kim PS, Zlatanic J, Korelitz BI, et al.: Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol 1999, 94:3254–3257.PubMedCrossRefGoogle Scholar
  37. 37.
    Sandborn WJ, Tremaine WJ, Wolf DC, et al.: Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 1999, 117, 527–535.PubMedCrossRefGoogle Scholar
  38. 38.
    Dubinsky M, Hassard P, Yang HY, et al.: 6-MP metabolite levels correlate with clinical response and drug toxicity in adult IBD. Am J Gastroenterol 1999, 94:2641(#A258).Google Scholar
  39. 39.
    Dubinsky M, Hassard P, Seidman EG, et al.: Serial 6-MP metabolite measurements identify 6-MP resistant IBD patients. Am J Gastroenterol 1999, 94:2641(#A259).Google Scholar
  40. 40.
    Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995, 332:292–297.PubMedCrossRefGoogle Scholar
  41. 41.
    Egan LJ, Sandborn WJ: Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996, 71:69–80. This is a superb summary of the pharmacology of MTx and its use in IBD.PubMedCrossRefGoogle Scholar
  42. 42.
    Lemann M, Chamiot-Prieur C, Mesnard B, et al.: Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther 1996, 10:309–314.PubMedCrossRefGoogle Scholar
  43. 43.
    Mack DR, Young R, Kaufman SS, et al.: Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. Pediatrics 1998, 132:830–835.CrossRefGoogle Scholar
  44. 44.
    Deslandres C: Methotrexate: an alternative treatment in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1999, 29:520(#A125).CrossRefGoogle Scholar
  45. 45.
    Fickert P, Hinterleitner TA, Wenzl HH, et al.: Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol 1998, 93:2529–2532.PubMedCrossRefGoogle Scholar
  46. 46.
    Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 1999, 44:625–628.PubMedCrossRefGoogle Scholar
  47. 47.
    Hassard PV, Vasiliauskas EA, Kam LY, et al.: Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn’s disease. Inflamm Bowel Dis 2000, in press.Google Scholar
  48. 48.
    Gershman G, Ament ME: Mycophenolate mofetil (MMF) induces remission in refractory pediatric patients with IBD. J Pediatr Gastroenterol Nutr 1999, 29:521(#A127).CrossRefGoogle Scholar
  49. 49.
    Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.PubMedCrossRefGoogle Scholar
  50. 50.
    Actis GC, Ottobrelli A, Pera A, et al.: Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993, 17:10–13.PubMedCrossRefGoogle Scholar
  51. 51.
    Abreu-Martin MT, Vasiliauskas EA, Gaiennie J, et al.: Continuous infusion cyclosporine (CSA) is effective for severe acute Crohn’s disease (CD) but for how long? Gastroenterology 1996, 110:A851.Google Scholar
  52. 52.
    Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1:48–63. This review summarizes the published literature and critically examines the role of CSA in the management of IBD.CrossRefGoogle Scholar
  53. 53.
    Hanauer SB, Smith MB: Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993, 88:646–649.PubMedGoogle Scholar
  54. 54.
    Present DH, Lichtiger S: Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 1994, 39:374–380.PubMedCrossRefGoogle Scholar
  55. 55.
    Brynskov J, Freund L, Rasmussen SN, et al.: A placebocontrolled, double-blind randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989, 321:845–850.PubMedCrossRefGoogle Scholar
  56. 56.
    Feagan BG, McDonald JWD, Rochon J, et al.: Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 1994, 330:1846–1851.PubMedCrossRefGoogle Scholar
  57. 57.
    Treem WR, Cohen J, Davis PM, et al.: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995, 38:474–479.PubMedCrossRefGoogle Scholar
  58. 58.
    Oppong K, Record CO: Neoral may be as effective as intravenous cyclosporine in the treatment of steroidresistant ulcerative colitis. Am J Gastroenterol 1998, 93:1188–1189.PubMedCrossRefGoogle Scholar
  59. 59.
    Sandborn WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 1997, 92:876–879.PubMedGoogle Scholar
  60. 60.
    Lowry PW, Weaver AL, Tremaine WJ, et al.: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatmentrefractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999, 5:239–245.PubMedCrossRefGoogle Scholar
  61. 61.
    Bousvaros A, Kirschner B, Werlin S, et al.: Oral tacrolimus treatment of severe colitis in children: long-term follow-up. J Pediatr Gastroenterol Nutr 1998, 27:463(#A2).CrossRefGoogle Scholar
  62. 62.
    Fellermann K, Ludwig D, Stahl M, et al.: Steroidunresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998, 93:1860–1866.PubMedCrossRefGoogle Scholar
  63. 63.
    Sands BE, Podolsky DK, Tremaine WJ, et al.: Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC). Gastroenterology 1996, 110:A1008.CrossRefGoogle Scholar
  64. 64.
    Derkx B, Taminiau J, Radema S, et al.: Tumour-necrosisfactor antibody treatment in Crohn’s disease. Lancet 1993, 342:173–174.PubMedCrossRefGoogle Scholar
  65. 65.
    Van Dullemen HM, van Deventer SJH, Hommes DW, et al.: Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129–135.PubMedCrossRefGoogle Scholar
  66. 66.
    Targan SR, Hanauer SB, van Deventer SJH, et al.: A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 1997, 337:1029–1035.PubMedCrossRefGoogle Scholar
  67. 67.
    Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor a in Crohn’s disease. Lancet 1997, 349:521–524.PubMedCrossRefGoogle Scholar
  68. 68.
    Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999, 340:1398–1405.PubMedCrossRefGoogle Scholar
  69. 69.
    Rutgeerts P, D’Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117:761–769.PubMedCrossRefGoogle Scholar
  70. 70.
    Vasiliauskas EA, Thomas DW, Schaffer S, et al.: Collaborative experience of open-label infliximab, in refractory pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1999, 29:525(#A144).CrossRefGoogle Scholar
  71. 71.
    Hadigan C, Baldassano R, Braegger CP, et al.: Pharmacokinetics of infliximab (anti-TNFa) in children with Crohn’s disease: a multicenter trail. J Pediatr Gastroenterol Nutr 1999, 29:525(#A143).CrossRefGoogle Scholar
  72. 72.
    Elliott MJ, Maini RN, Feldmann M, et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344:1125–1127.PubMedCrossRefGoogle Scholar
  73. 73.
    Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:119–133. This paper reviews issues related to the use of the anti-TNFa agents infliximab, CDP571, and etanercept in IBD.PubMedCrossRefGoogle Scholar
  74. 74.
    Remicade product information. Physicians Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 54th ed.:927–930.Google Scholar
  75. 75.
    Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al.: An open-label pilot study of low-dose thalidomide in chronically-active, steroid-dependent Crohn’s disease. Gastroenterology 1999, 117:1278–1287.PubMedCrossRefGoogle Scholar
  76. 76.
    Wettstein AR, Meagher AP: Thalidomide in Crohn’s disease. Lancet 1997, 350:1445–1446.PubMedCrossRefGoogle Scholar
  77. 77.
    Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999, 117:1271–1277.PubMedCrossRefGoogle Scholar
  78. 78.
    Odeka EB, Miller V: Thalidomide in oral Crohn’s disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 1997, 25:250–251.CrossRefGoogle Scholar
  79. 79.
    Weinstein TA, Sciubba JJ, Levine J: Thalidomide for the treatment of oral aphthous ulcers in Crohn’s disease. J Pediatr Gastroenterol Nutr 1999, 28:214–216.PubMedCrossRefGoogle Scholar
  80. 80.
    Belluzzi A, Brignola C, Campieri M, et al.: Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996, 334:1557–1560.PubMedCrossRefGoogle Scholar
  81. 81.
    Sandborn WJ: Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999, 94:1161–1171.PubMedCrossRefGoogle Scholar
  82. 82.
    Burakoff R: Less commonly used therapies for IBD or treatments on the fringe. Proceedings of the Inflammatory Bowel Disease Workshop held in Vail, Colorado, March 22 and 23, 1998. Inflamm Bowel Dis 1998, 4:308–317. The roles of nicotine, fish oil, short-chain fatty acids, hydroxychloroquine, antibiotics, and enteral nutrition as a primary therapy in IBD are reviewed and discussed.PubMedCrossRefGoogle Scholar
  83. 83.
    van Deventer SJ, Elson CO, Fedorak RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997, 113:383–389.PubMedCrossRefGoogle Scholar
  84. 84.
    Motil KJ, Grand RJ: Nutritional management of inflammatory bowel disease. Pediatr Clin N Am 1985, 32:447–469.Google Scholar
  85. 85.
    Seidman E, LeLeiko N, Ament M, et al.: Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991, 12:424–438.PubMedCrossRefGoogle Scholar
  86. 86.
    Calam J, Crooks PE, Walker RJ: Elemental diets in the management of Crohn’s perianal fistulae. J Parenter Enter Nutr 1980, 4:4–8.CrossRefGoogle Scholar
  87. 87.
    Teahon K, Bjarnason I, Pearson M, et al.: Ten years experience with an elemental diet in the management of Crohn’s disease. Gut 1990, 31:1133–1137.PubMedGoogle Scholar
  88. 88.
    Lavy A, Weisz G, Adir Y, et al.: Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterology 1994, 19:202–205.CrossRefGoogle Scholar
  89. 89.
    Gryboski JD: Crohn’s disease in children 10 years old and younger: comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994, 18:174–182.PubMedCrossRefGoogle Scholar
  90. 90.
    Motil KJ, Grand RJ, Davis-Kraft L, et al.: Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993, 105:681–691.PubMedGoogle Scholar
  91. 91.
    Kanof ME, Lake AM, Bayless TM: Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988, 95:1523–1527.PubMedGoogle Scholar
  92. 92.
    Markowitz J, Grancher K, Rosa J, et al.: Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993, 16:373–380.PubMedCrossRefGoogle Scholar
  93. 93.
    Griffiths AM, Nguyen P, Smith C, et al.: Growth and clinical course of children with Crohn’s disease. Gut 1993, 34:939–943.PubMedGoogle Scholar
  94. 94.
    Homer DR, Grand RJ, Colodny AH: Growth, course, and prognosis after surgery for Crohn’s disease in children and adolescents. Pediatrics 1977, 59:717–725. This is a retrospective analysis of postoperative outcomes of children with CD as measured by growth patterns following surgery.PubMedGoogle Scholar
  95. 95.
    McLain BI, Davidson PM, Stokes KB, et al.: Growth after gut resection for Crohn’s disease. Arch Dis Child 1990, 65:760–762. This study examines the effect surgical resection of diseased bowel on subsequent growth in children with CD.PubMedGoogle Scholar
  96. 96.
    Gokhale R, Favus MJ, Karrison T, et al.: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998, 114:902–911.PubMedCrossRefGoogle Scholar
  97. 97.
    Van Citters G, Lin HC: Oleic acid improves drug absorption in patients with inflammatory bowel disease. Gastroenterology 1998, 114:A1105(#G4521).Google Scholar
  98. 98.
    Bayless TM, Harris ML: Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990, 74:21–28.PubMedGoogle Scholar
  99. 99.
    Pimentel M, Lin HC: Eradication of small intestinal bacterial overgrowth decreases symptoms in Crohn’s Disease. Am J Gastroenterol 1999, 94:2647(#A282). This study suggests that recognition and treatment of small intestinal bacterial overgrowth eliminates or reduces symptoms that might otherwise be attributed to a flare of CD.Google Scholar
  100. 100.
    Thomas AO, Rhodes J, Green JT: Inflammatory bowel disease and smoking-a review. Am J Gastroenterol 1998, 93:144–149.PubMedGoogle Scholar
  101. 101.
    Bjarnason I, Price AB, Zanelli G, et al.: Clinicopathological features of nonsteroidal antiinflammatory druginduced small intestinal strictures. Gastroenterology 1988, 94:1070–1074.PubMedGoogle Scholar
  102. 102.
    Facklis K, Plevy SE, Vasiliauskas EA, et al.: Crohn’s disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Dis Colon Rectum 1999, 42:601–606.PubMedCrossRefGoogle Scholar
  103. 103.
    Fleshner PR, Vasiliauskas EA, Kam L, et al.: High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch anal anastomosis. Gastroenterology 1999, 116:A716(#G3107).Google Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Eric Vasiliauskas
    • 1
  1. 1.Inflammatory Bowel Disease Center, Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations